A comparative study of quality of life with respect to EORTC scale in lung cancer patients undergoing chemo radiation

Praghnya S. Tejale; Vijay K. Mahobia; Ashok K. Diwan

doi:10.18203/2320-6012.ijrms20251435

Authors

Praghnya S. Tejale Department of Radiotherapy, Government Medical College, Nagpur, Maharashtra, India
Vijay K. Mahobia Department of Radiotherapy, Government Medical College, Nagpur, Maharashtra, India
Ashok K. Diwan Department of Radiotherapy, Government Medical College, Nagpur, Maharashtra, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20251435

Keywords:

Lung cancer, ECOG, EORTC, Quality of life

Abstract

Background: In lung cancer patient's data regarding comparison of quality-of-life pre and post treatment as per EORTC score is sparse. So, we conducted this study on lung cancer patients to compare the quality of life.

Methods: Demographic data were collected from new lung cancer patients (not taking treatment elsewhere) attending the Radiation and Oncology Department of Government Medical College, Nagpur. ECOG performance score noted before starting treatment. Pre-treatment and 6 weeks’ post-treatment quality of life score measured according to EORTC QLQ-C30 and EORTC QLQ-LC13 and compared. Treatment given was either chemotherapy, radiotherapy or chemo-radiotherapy according to standard guidelines.

Results: 79 patients received treatment and completed regular follow-up. The mean age of the patients was 56.06 years (SD±10.46). The number of male patients was 47, and the number of female patients was 32. The number of patients with ECOG scores 0, 1, 2, 3, and 4 was 3 (3.8%), 35 (44.3%), 24 (30.4%), 14 (17.7%), and 3 (3.8%), respectively. EORTC QLQ-C30 score pre- and post-treatment was 70.14 (±16.309) and 53.58 (±16.445), respectively (p<0.001).

Conclusions: QoL in lung cancer patients improves after chemotherapy, radiotherapy, or chemo-radiotherapy. EORTC is a simple and useful score system for comparing pre- and post-treatment QoL.

Metrics

Metrics Loading ...

References

Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999;17(10):3188-94. DOI: https://doi.org/10.1200/JCO.1999.17.10.3188

Ellis PA, Smith IE, Hardy JR, Nicolson MC, Talbot DC, Ashley SE, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer. 1995;71(2):366-70. DOI: https://doi.org/10.1038/bjc.1995.74

Tummarello D, Graziano F, Isidori P, Cellerino R. Symptomatic, stage IV, non-small-cell lung cancer (NSCLC): response, toxicity, performance status change and symptom relief in patients treated with cisplatin, vinblastine and mitomycin-C. Cancer Chemother Pharmacol. 1995;35(3):249. DOI: https://doi.org/10.1007/BF00686556

Census India, Government of India. Report on medical certification of cause of death. 2013. Available at: http://www.censusindia.gov.in/2011-documents/mccd_Report1/Mccd_2013.pdf. Accessed on 24 March 2025.

Ganesh B, Sushama S, Monika S, Suvarna P. A Case-control Study of Risk Factors for Lung Cancer in Mumbai, India. Asian Pac J Cancer Prev. 2011;12:357-62.

Kearney N, Richardson A. Nursing Patients with Cancer: Principles and Practice. 1st edition. Philadelphia, PA: Churchill Livingstone. 2006.

Alptekin S, Gönüllü G, Yücel I, Yaris F. Characteristics and quality of life analysis of caregivers of cancer patients. Med Oncol. 2010;27:607-17. DOI: https://doi.org/10.1007/s12032-009-9256-2

Montazeri A. Quality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health Qual Life Outcomes. 2009;7:102. DOI: https://doi.org/10.1186/1477-7525-7-102

Hechtner M, Eichler M, Wehler B, Buhl R, Sebastian M, Stratmann J, et al. Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study. J Thorac Oncol. 2019;14(3):420-35. DOI: https://doi.org/10.1016/j.jtho.2018.11.019

Słowik-Gabryelska A. The quality of life after chemotherapy in advanced non-small cell lung cancer patients. Pol Merkur Lekarski. 1999;6(31):18-22.

Singh N, Aggarwal AN, Gupta D, Behera D, Jindal SK. 14. Unchanging clinico-epidemiological profile of lung cancer in north India over three decades. Cancer Epidemiol. 2010;34:101-4. DOI: https://doi.org/10.1016/j.canep.2009.12.015

Malik PS, Sharma MC, Mohanti BK, Shukla NK, Deo S, Mohan A, et al. Clinico-pathological profile of lung cancer at AIIMS: a changing paradigm in India. Asian Pac J Cancer Prev. 2013;14:489-94. DOI: https://doi.org/10.7314/APJCP.2013.14.1.489

Noronha V, Dikshit R, Raut N, Joshi A, Pramesh CS, George K, et al. Epidemiology of lung cancer in India: focus on the differences between non-smokers and smokers: a single-centre experience. Indian J Cancer. 2012;49:74-81. DOI: https://doi.org/10.4103/0019-509X.98925

Behera D, Balamugesh T. Lung cancer in India. Indian J Chest Dis Allied Sci. 2004;46(4):269-81.

Jindal SK, Behera D. Clinical spectrum of primary lung cancer: Review of Chandigarh experience of 10 years. Lung India. 1990;8:9498.

Ganie, Ahmad F, Wani ML, Lone H, Wani SN, Hussain SA. Carcinoma lung: Clinical presentation, diagnosis, and its surgical management. J Assoc Chest Phys. 2013;1(2):38-43. DOI: https://doi.org/10.4103/2320-8775.123208